胰岛素类生长因子-1受体在烟草吸烟相关肺癌发展中的作用
Ayaz Shahid1, Shaira Gail Santos2, Carol Lin1
1Department of Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, Pomona, CA 91766, USA.
Biomedicines
|March 28, 2024
概括
烟草中的致癌物激活胰岛素样生长因子1受体 (IGF-1R) 途径,促进肺癌和化疗耐药性. 向IGF-1R具有挑战,因为它与胰岛素受体相似,需要组合疗法来有效治疗肺癌.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 致癌的发生是致癌的产生.
背景情况:
- 肺癌是全球主要的健康问题,受体氨酸激酶 (RTK) 的遗传异常与其发展有关.
- 胰岛素样生长因子1受体 (IGF-1R) 途径对肺癌进展至关重要,影响细胞生长,存活和治疗耐药性.
- 众所周知,烟草烟雾中的致癌物激活IGF-1R,有助于肺癌的发病和耐化疗.
研究的目的:
- 审查烟草烟雾特异性致癌物和IGF-1R途径在肺癌发生过程中的复杂关系.
- 探索IGF-1R在促进肺癌和化疗耐药性的作用.
- 突出IGF-1R在肺癌治疗中的挑战和潜在策略.
主要方法:
- 关于RTKs,IGF-1R,肺癌和烟草致癌物的现有研究的文献综述.
- 对将IGF-1R激活与肺癌发展和治疗耐药性联系起来的分子机制的分析.
- 检查针对IGF-1R的治疗策略.
主要成果:
- 烟草烟雾衍生的致癌物激活IGF-1R通路,推动肺癌的生长和生存.
- 高IGF-1R表达与预后不佳和对常规癌症治疗的耐药性相关.
- 针对IGF-1R用于肺癌治疗的目标因其与胰岛素受体的结构相似性而复杂.
结论:
- IGF-1R途径是烟草诱导的肺癌发生和化疗耐药性的关键调解者.
- 开发有效的IGF-1R抑制剂治疗肺癌需要克服与特异性和潜在副作用相关的挑战.
- 涉及IGF-1R抑制和其他向药物的组合疗法可能为治疗肺癌提供了一个有希望的方法.
相关概念视频
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
TGF - β Signaling Pathway
7.3K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.3K
Insulin: The Receptor and Signaling Pathways
1.2K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.2K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Regulation of Angiogenesis and Blood Supply
2.6K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.6K
PI3K/mTOR/AKT Signaling Pathway
3.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.5K


